COMPANY:

Arima Genomics

"The investigators observed high concordance with standard techniques and also identified additional clinically relevant findings that had not been detected in prior routine workups....The authors note that a key advantage of Arima’s method is its whole-genome view of rearrangements in a single assay, which can help uncover unexpected or uncommon rearrangements that may have diagnostic or therapeutic implications."

"Arima Genomics is making a concerted push to expand its business into cancer diagnostics, following the demonstration of its sequencing-based chromosome conformation assay kits to identify cancer driver mutations."

"Arima Genomics, Inc...and Pierian now a part of Velsera...announced co-marketing and licensing agreements that will provide enhanced gene fusion detecting capabilities to clinical labs. Under the terms of the agreement, Velsera will integrate Arima Genomics’ targeted next-generation sequencing (NGS) testing pipelines into the Pierian Clinical Genomics Workspace (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis, interpretation, and reporting. The combined solution will enable clinical laboratories to more easily implement sample-to-answer Arima gene fusion testing, helping them identify gene fusions and other structural variants."

"Arima Genomics, Inc...announced an agreement to make an Arima next-generation sequencing-based test available to clinicians for patient management through Protean BioDiagnostic’s CLIA-certified, CAP-accredited laboratory in Orlando, Florida. The new testing service, using Arima’s novel genomic technology, will identify clinically actionable gene fusions in tumor tissue from patients with cancer, and is anticipated to be available for order in the first half of 2023."